Research Paper Volume 15, Issue 16 pp 8367—8383

Figure 3. Characteristics of circFAM169A in CRC cells. (A) The diagram represents the structure of circFAM169A and the arrows denote the different primers. (B) The reverse transcription–PCR (RT-PCR) products from different primers were detected by agarose gel electrophoresis. (C) Samples were treated with RNase (+) or buffer (−), and the expression of circFAM169A was determined by quantitative RT–PCR (qRT–PCR). (D) SW480 cells were treated with (+) or without (−) actinomycin D, and the stability of circFAM169A was assessed by qRT–PCR. (E) Cells were analyzed by immunofluorescence cytochemistry. Scale bar = 20 μm. (F) The location of circFAM169A, GAPDH, and Malat1 in CRC cells. (G) Relative expression of circFAM169A in 20 paired CRC tumor and adjacent normal tissues determined using qRT–PCR. (H) ROC curves illustrating the capacity of circFAM169A to distinguish between tumors and adjacent tissues from patients with CRC. All data are presented as means ± standard deviation (SD) (n = 3 independent experiments). ^*p ≤ 0.05, ^**p ≤ 0.01, ^***p ≤ 0.001, and ^****p ≤ 0.0001.